Biosimilars: Proxy Debates and more Stumbling Blocks on the Way to the European Market
Read what representatives from EU Commission, EMEA, CRO, Hospital Pharmacists, Amgen and Sandoz told in pharma industry and regulators from Europe and the US during a controversial discussion.